Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment

Certain organ-on-a-chip (OoC) systems have been validated to show superior predictive capabilities compared to planar, static cell cultures, and animal models for drug evaluations. One of the ongoing initiatives led by OoC developers is bridging the academia-to-industry gap in hope of gaining wider adoption by end-users: academic biological researchers and industry. In this article, we discuss several recommendations that can help drive the translation of OoC in the market. We first lay out some of the key challenges faced by OoC developers before highlighting some of the existing advances in OoC platforms. Thereafter, we suggest recommendations that OoC developers can deliberate for the translation of OoC into the industry.